Editor's key points † There is considerable need for opioids with reduced tolerance. † A series of bifunctional opioid receptor ligands was tested for receptor binding and function. † Addition of a linker did not impair receptor binding, but reduced m opioid receptor functional activity, indicating the need for alternate approaches to reducing tolerance.
Opioid use in the pain clinic is hampered by development of tolerance, providing a dilemma in the treatment of chronic pain. The underlying causes of chronic pain are complex, the origins of which include a wide range of diseases and/or injuries, making effective treatment difficult. 1 For instance, the treatment of chronic pain in cancer has been shown to be ineffective in up to 50% of patients in the last year of their lives. 2 3 Most clinically available opioids act solely at the mu opioid peptide (MOP) (m) receptor; a member of the G i/o -protein coupled opioid receptor family of receptors, which also includes the delta opioid peptide (DOP) (d), kappa opioid peptide (KOP) (k) and nociceptin/orphanin FQ opioid peptide (NOP) receptors. Substantial evidence has implicated the DOP receptor 1 4-6 in the development of tolerance, hastening the development of multifunctional opioids. The mechanisms underlying the development of tolerance are varied, involving a multitude of cellular functions, receptor properties and signalling processes, such as receptor internalisation and b-arrestin recruitment. 7 A large body of evidence, including various molecular studies 4 8 9 and work in mouse models, 10 11 has implicated other members of the opioid receptor family, specifically the DOP receptor, as potential mediators and/or instigators in the development of tolerance. The involvement of two, or more, opioid receptors in the progression of tolerance has provided a target for the development of drugs with multiple pharmacophores, i.e. bivalent or bifunctional ligands. Bivalent and bifunctional ligands could present more predictable pharmacokinetic and pharmacodynamic traits than two separately acting ligands. Synergy between two conjoined pharmacophores can also lead to improved potency, as well as a potential reduction in side-effects. 6 Previous attempts at developing bivalent ligands have focused on adaptations or derivatives of semi-synthetic or peptide structures. 12 13 We studied chemical adaptations of fentanyl (N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenylpropanamide), a clinically available synthetic opioid, to accept linker molecules and a second pharmacophore (DmtTic (2 ′ ,6 ′ -dimethyl-L-tyrosyl-1,2,3,4-tetrahydrisoquinoline-3-carboxylic acid)). Previous studies have reported the synthesis and chemical adaptation of these carboxy-fentanyl molecules through conjugation with DOP agonists (enkephalins) and neurokinin-1 (NK-1) antagonists. 14 15 Fentanyl is a potent MOP agonist (10 fold greater than morphine) used in the treatment of pain in a clinical setting. Moreover, fentanyl is hydrophobic allowing greater access to the central nervous system than, for instance, morphine. 16 The potent analgesic activity and high bioavailability of fentanyl make it an ideal model on which to base a mixed opioid. The second pharmacophore chosen for the development of these new bivalent compounds is the DOP antagonist Dmt-Tic. Dmt-Tic has a long history of use in the development of multi-pharmacophoric compounds, and it has been demonstrated that C-terminal chemical modifications of Dmt-Tic are tolerated, thus making it a good candidate for the development of a [MOPagonist]-[DOPantagonist] complex. 17 -20 We characterised the binding and functional activity of five newly synthesized fentanyl (MOP)/Dmt-Tic (DOP) bivalent compounds. As shown in previous studies, linker length can affect the affinity and efficacy of either pharmacophore; with this in mind we have examined spacer length between the MOP and DOP pharmacophores. 13 21 Finally we explored whether these novel bivalent molecules produce changes in signalling in G-protein activation and b-arrestin recruitment assays. 
Membrane preparation
Cells were harvested, homogenised, and membrane fragments were resuspended in either a wash buffer consisting 
Beta-Arrestin assay
Assays were prepared as described in the DiscoveRx (UK) PathHunter w Assay protocol. Cells were incubated for 24 h (human OPRM1, MOP) or 48 h (human OPRD1, DOP) as suggested in 96 well plates provided. Following the desired incubation period, desired concentrations of compounds were added to the wells, and incubated at 378C for 90 min. For morphine and fentanyl, at MOP, and DPDPE, at DOP, a range of concentrations was used (1 nM -10 mM). At MOP, only maximum concentrations (10 mM) compounds #9 -#13 were used. In antagonist studies at DOP, 10 nM of Dmt-Tic was incubated in a range of concentrations of DPDPE (1 nM-10 mM). High concentrations of DPDPE (1 mM) were incubated with 100 nM ( EC 80 ) of compounds #9-#13 to determine antagonist activity. The final development reagent was added and plates were incubated at room temperature for 1 h. Plates were read using a Dynex MLX luminometer, Dynex Technologies, UK, set at 1 sec/well to measure relative light units (RLU).
Data analysis
Data are expressed as mean(SEM (n)) experiments. Results were analysed and graphs were fitted using GraphPad PRISM V6.02 (San Diego, USA). In displacement binding studies, the concentration of competitor which produced 50% displacement (IC 50 ) was corrected for competing mass of radiolabel according to Cheng (Fig 1A) . pEC 50 values of #10(7.13) and #11(7.52) were not significantly different to that of fentanyl (7.31) at MOP. The pEC 50 for #9 (6.74) was significantly different to fentanyl. E max values, compared with fentanyl (3.88), for compounds #9:1.18; #10:2.19; #11:1.98 were significantly different. Relative intrinsic activity (a-E max ) and potency (pEC 50 ) values are summarised in Table 3 .
Since compounds #9, #10 and #11 showed reduced efficacy at CHO h MOP, these were screened in an antagonist assay ( Fig. 1B; Table 2 ). A fixed concentration (1 mM) of the bivalent compounds was added to varying concentrations of fentanyl in CHO hMOP cells; there was a rightward shift in the fentanyl concentration response curve. Both #10 and #11 displayed E max values similar to fentanyl ( Table 2 ). E max in the presence of #9 was significantly different to fentanyl. The pK b values were: #9 (6.87), #10 (7.55) and #11 (7.81).
In (Fig. 2A) . When compounds #9, #10 and #11 were co-incubated with the DOP agonist DPDPE, all compounds caused a rightward shift in the concentration-response curves (Fig. 2B) . Compounds, #10 and #11, produced pK b values of 8.06 and 8.1, respectively. Compound #9 had a pK b of 6.85 (Table 3) .
Functional assays were performed in cell membranes expressing the KOP and NOP receptor; bivalents #9 -#11 showed no agonist or antagonist activity at these receptors ( Fig. 3A and B) .
With respect to reference compounds RRC2, RRC3 and RRO; compounds #9-#11 restore MOP binding. The substantial loss in MOP efficacy compared with fentanyl indicated an alteration in the interaction between the fentanyl pharmacophore and the MOP receptor. not significantly different from fentanyl (8.13) . At the DOP receptor, #12(9.67) and #13(9.71) both showed increased affinity for the DOP receptor, when compared with both #11(8.37) and the parent compound Dmt-Tic-OH (8.95). Differences in binding affinity between the two Gly-linker extended molecules were evident at the KOP receptor; #12 (8.14) displaying nanomolar affinity. While there was no significant difference in the binding affinities of #11(7.13) and #13(7.35), #12 showed statistical differences from both of these compounds. The Gly extended compounds showed either weak (#13; 6.63), or no affinity (#12; inactive) for the NOP receptor (Table 2 ).
Displacement binding assays-Final compounds #12 and #13

GTPg[ 35 S] functional assays-Final compounds #12 and #13
The Gly-extended compounds #12 and #13 failed to stimulate the binding of GTPg[
35 S] with no efficacy at the MOP receptor ( Fig. 4A ; Table 3 ). At 300 nM, compounds #12 and #13 behaved as weak antagonists with pK b values of 6.91and 7.05, respectively (Fig. 4B) . Compounds #12 and #13 showed no activity at the DOP receptor (Fig. 5A, Table 3 ). However, when co-incubated with the DOP agonist DPDPE, both #12 (pK b :9.42) and #13 (9.00) produced a rightward shift in the agonist concentration response curve (Fig. 5B, Table 3 ).
Since #12 and #13 displayed binding affinity for KOP, GTPg [ 35 S] functional assays were performed. Both compounds were inactive (Fig. 6A) . In antagonist experiments, 300 nM and 1 mM for #12 and #13, respectively, produced a weak but measurable rightward shift in the concentration response curve when co-incubated with dynorphin-A. Compound #12 and #13 produced pK b values of 6.96 and 6.45, respectively (Fig. 6B) . In view of the low affinity at NOP for #12 and #13 functional assays were not performed.
Beta-Arrestin assays
b-arrestin recruitment in MOP cells was determined for fentanyl and morphine in CHO h MOP cells lines (Fig. 7A) . Maximally effective concentrations of bivalent compounds were used to compare against fentanyl and morphine (Fig. 7B) . Fentanyl (E max of 13.62(0.45)) produced a greater b-arrestin recruitment than morphine (E max : 10.80(0.38)). Fentanyl (pEC 50 : 7.45 (0.07)) also has increased potency compared with morphine (6.88(0.12)). The potency of fentanyl for b-arrestin recruitment was similar to its potency of GTPgS activation (Table 2) . When compared with the maximum response of fentanyl, the bivalent ligands showed poor ability to recruit b-arrestins. Response from the maximum concentration tested in rank order was: #10 (2.72),#11 (2.40) ,#9 (1.58) ,#13 (1.58) ,#12 (1.29). The ability of these compounds to recruit b-arrestins was significantly different when compared with fentanyl. When compared with fentanyl, the intrinsic activity of these compounds was: #9:0.12; #10:0.20; #11:0.18; #12:0.09 and #13:0.12.
In DOP cells, ability of DPDPE to recruit and Dmt-Tic (the parent pharmacophore) to inhibit b-arrestin recruitment were measured (Fig. 8A) . DPDPE produced a concentration dependent and saturable increase in b-arrestin recruitment with pEC 50 .29)), the presence of #9 (7.43), #10 (9.51) and #11 (9.56) significantly reduced the ability of DPDPE to recruit b-arrestins, indicating antagonist activity. The presence of either 10 nM #12 (6.44) or 10 nM #13 (5.56) led to +50% reduction in the ability of DPDPE to recruit b-arrestin, suggesting potent antagonist activity at the DOP receptor (Fig. 8B) .
Discussion
Linking of the Dmt-Tic pharmacophore to fentanyl produced compounds that displayed binding affinities at MOP comparable to that of the parent compound fentanyl, with the exception of #9. Compound #9 showed a decrease in binding affinity for MOP. Final compounds #9-13 displayed affinity for the DOP receptor consistent with the presence of a Dmt-Tic pharmacophore. Compounds #10 and #11 displayed similar binding affinity to that of Dmt-Tic, whilst compound #9 again showed a decrease in binding affinity. Compounds with glycine-extended linkers (#12 and #13) showed a relative increase in binding at DOP. In functional studies, all compounds showed either weak partial agonist activity or no functional activity at MOP relative to fentanyl, with compounds #9, #10 and #11 acting as weak partial agonists, while the extended linker compounds (#12 and #13) showed no functional activity at this receptor. In antagonist assays at MOP, compounds #10 and #11 antagonised fentanyl, producing pK b values similar to both their pK i and pEC 50 values, inherent qualities of a partial agonist. Compounds #12 and #13 displayed low antagonist affinity at MOP, but displayed increased antagonist affinity, when compared with Dmt-Tic, at DOP. The antagonist affinity displayed at DOP by #12 and #13 matched their pK i values for DOP. The weak intrinsic activity, regarding GTPg[ 35 S] binding, was mirrored in their ability to recruit b-arrestins. Compounds #10 and #11 produced the highest recruitment; however this was approximately 5-fold lower than that of the parent compound fentanyl. MOP and DOP in neurones and cells in the pain pathway has led to the hypothesis of a heterodimer, with unique signalling properties that influence opioid tolerance. The involvement of the DOP receptor in this heterodimer is believed to include differential phosphorylation and recruitment of b-arrestins, such that selectivity for the ubiquitination pathway is favoured after endocytosis. 34 35 This makes it an ideal target for a drug with dual selectivity. Due to the more predictable pharmacokinetics and pharmacodynamics of a single drug, previous work has either focused on novel bifunctional drugs (UFP-505) or bivalent pharmacophores (MDAN21). 6 13 In the development of drugs with dual agonist targets, it is important that the individual affinities produced by the drug for different receptors are similar. This would remove any favourability for a particular receptor, thereby increasing the possibility of the drug acting at both target sites. In the case of both our compounds and UFP-505, their affinities for DOP are higher than their affinities for MOP. However, since both have antagonist activity at DOP, this could be beneficial as a higher affinity for DOP ensures that DOP is fully blocked when MOP is activated. Due to the differences in functional activity seen with compounds #9, #10 and #11 compared with fentanyl, it was initially hypothesised that the distance between the pharmacophores affected their ability to interact with MOP. The importance of spacer molecules (size, distance, charge) has been previously demonstrated in a number of models, none more so effectively than in the development of the MDAN series of compounds. 13 In order to validate this, we extended the linker molecules, using the amino acid glycine, of the most efficacious compound, #11. Either a single glycine molecule (#12) or two glycine molecules (#13) were added to the linker structure. The increase in spacer length between the MOP and DOP pharmacophores completely prevented MOP receptor activation. In contrast, DOP antagonist activity was retained. These results inferred that the changes of efficacy determined here, most likely lay in a combination of adaptation of the chemical structure of the fentanyl conjugates and linker length. It should be emphasized that simple functionalization of fentanyl with an acidic moiety as in RRC2, RRC3 and RRO produced loss of MOP binding. b-arrestin recruitment has been implicated in the internalisation and recycling or ubqiuitination of opioid receptors. 36 In this study, bivalent compounds showed poor efficacy in general and substantially reduced ability to recruit b-arrestins to the MOP receptor, collectively suggesting a limited ability to promote receptor internalisation. Interestingly, the bivalent ligand with the shortest linker length (#9) displayed weaker interactions with MOP. The compound displayed weak partial agonist activity, potency and antagonist affinity which was not similar to that of its binding affinity. The similarity of the binding affinity of compound #9 to fentanyl suggests that the initial interactions between drug and receptor are not altered. However, due to the marked decrease in potency and antagonist binding affinity, when compared with the pK i , we hypothesise that the close proximity of the two pharmacophores negatively affects the ability of the compound to engage with the binding pocket of the MOP receptor to produce a functional response. Similar results have been recently obtained with MOP/DOP bivalent ligands composed of morphine and Dmt-Tic pharmacophores. 37 Moreover, in this case the molecules lose MOP functional activity, behaving as MOP partial or antagonist ligands. In contrast, both fentanyl and morphine Dmt-Tic bivalent ligands maintain potent DOP antagonist properties corroborating the evidence that C-terminal modifications of Dmt-Tic pharmacophore are tolerated. 38 39 Limitations While the compounds demonstrated the desired antagonist affinity at DOP, they demonstrated poor, or no, efficacy at MOP in our high expression system. Coupled with a modest antagonist affinity at the MOP receptor, these compounds would be predicted to have absent or ultra-low analgesic action. In the clinical setting the goal would be to design a high efficacy MOP agonist (retain the activity of fentanyl) coupled with DOP antagonism. The main limitation of our study is the lack of in vivo testing. However, we would argue that as the MOP agonist activity is lost there would be little point in undertaking antinociceptive testing in vivo.
In conclusion, the development of clinically available opioids with reduced tolerance profile is of high importance; MOP agonist -DOP antagonist ligands are possible candidates. In this study, the potent clinical MOP opioid fentanyl was linked to the DOP antagonist, Dmt-Tic to produce a new series of bivalents. This series of compounds was unable to retain the potent functional activity of fentanyl at MOP whilst retaining potent antagonist activity at DOP.
